Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28340729 | 0.83 | KMT2A (0.51) | SRD5A2MGLLKMT2AHSD11B1MEN1 | |
| SCHEMBL3113279 | 0.83 | SRD5A2 (0.58) | MCL1SRD5A2HTR2ACPB1MGLL | |
| SCHEMBL1865557 | 0.82 | AKR1C3 (0.49) | MCL1SRD5A2MTNR1AMTNR1BHTR2A | |
| SCHEMBL1865563 | 0.82 | AKR1C3 (0.49) | MCL1SRD5A2MTNR1AMTNR1BHTR2A | |
| SCHEMBL1865559 | 0.82 | AKR1C3 (0.49) | MCL1SRD5A2MTNR1AMTNR1BHTR2A | |
| SCHEMBL7279058 | 0.81 | MGLL (0.48) | MCL1SRD5A2HTR2ACPB1MGLL | |
| SCHEMBL8815571 | 0.81 | MCL1 (0.45) | MCL1SRD5A2MTNR1AMTNR1BHTR2A | |
| SCHEMBL25740889 | 0.79 | ACHE (0.44) | MCL1SRD5A2MTNR1AMTNR1BHTR2A | |
| SCHEMBL25740890 | 0.79 | ACHE (0.44) | MCL1SRD5A2MTNR1AMTNR1BHTR2A | |
| SCHEMBL18681661 | 0.79 | ACHE (0.44) | MCL1SRD5A2MTNR1AMTNR1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124412-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124412-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | ULK1 3517/4885MCL1 316/4885SRD5A2 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.